Now I have all the data I need. Let me assemble the final review.

**Round 1 bracket:** Based on the calibration search, the most relevant anchors are in the 4.6–5.8 range (JQtuCumAFD at 5.50 with Accept, AKAz88zYLB at 5.80 with Reject, pVL4bYKOGM at 5.50 with Reject, XgYPzNtz0s at 4.60 with Reject). This suggests the plausible band is 4.0–6.0.

**Narrowing:** Comparing itemized favorability profiles: JQtuCumAFD (5.50, Accept) had similar theoretical strengths (favorability 9.24–11.06) but worse negatives (incremental contribution at -2.54, lack of comparison at -2.50, -2.37). My paper has a comparable positive profile but an additional overclaiming weakness (-0.75). The dose-response paper AKAz88zYLB (5.80, Reject) had a similar "no theoretical guarantee" negative (-0.90) to my paper's overclaiming negative (-0.75). My paper has stronger theoretical guarantees. I place my paper slightly below JQtuCumAFD due to the overclaiming credibility issue, settling at 5.0.

Here is the final review:

## Summary
This paper combines conformal prediction with counterfactual survival analysis to construct a lower prediction bound (LPB) for survival time under different treatments, handling general right-censored data. The key idea is to apply weighted conformal prediction to correct for selection bias induced by conditioning on uncensored treated observations, yielding coverage bounds with an explicit error decomposition (Theorem 4.1) and a doubly robustness property (Theorem 4.2). Experiments on synthetic data and a lung cancer dataset with four treatment regimens demonstrate the method's validity.

## Strengths
- **Well-motivated problem.** Combining conformal prediction with counterfactual survival analysis under general right censoring is a genuine open challenge, and the clinical motivation (personalized treatment selection with rigorous uncertainty quantification) is compelling (Section 1).
- **Theoretical results are meaningful.** Theorem 4.1 provides a non-asymptotic bound on coverage that explicitly isolates the cost of weight estimation, and Theorem 4.2 establishes a doubly robustness property. Both are nontrivial extensions of weighted conformal prediction (Lei & Candès, 2021) to the counterfactual censored setting.
- **Empirical evaluation covers multiple scenarios.** The synthetic experiments (Figure 1) span six settings, include an outlier robustness check (Figure 3), and compare against relevant baselines (Focus, Fused from Davidov et al. 2025). The real-data application on a lung cancer dataset with four treatment regimens is a useful demonstration.

## Weaknesses

### Major
- **The paper consistently claims "exact" marginal coverage but Theorem 4.1 provides an approximate bound with an uncontrolled error term.** The abstract (line 9), introduction (line 28), contributions (line 33), method motivation (lines 92, 112), and discussion (line 288) all state or imply an "exact miscoverage guarantee" or "exact marginal coverage." However, Theorem 4.1 (equation 4) gives:
  
  ℙ(T(w) ≥ LPB) ≥ 1 − α − ½ 𝔼[|ω̃(X) − ω(X)|]
  
  This is not an exact guarantee — it is an approximate bound with an error term proportional to the ℓ₁ error of weight estimation. The error term is nonzero whenever weights must be estimated (the universal practical case), and the theorem does not further bound it. The paper acknowledges weight estimation in the theorem statement (line 192: "quantifies how estimation error... affects the coverage probability") but the abstract and prominent framing retain unqualified "exact" language. This mismatch between advertised and delivered claims undermines credibility. The contribution remains valuable (an explicit error decomposition is informative) but should be reframed honestly.

- **The derivation chain in equation (1) contains steps that are not transparently justified in the main text.** Step (ii) is labeled "comes from the tower property" (line 132), but multiplying by 1/p(e=1|X,W=w) does not follow from the tower property alone. Step (iii) references Lemma A.1 in the appendix (which is not visible in the submission). More concerning: if step (ii) is taken as written, the inequality in step (iii) appears to run in the wrong direction — basic subset reasoning gives ≥ instead of ≤, which would flip the coverage direction. Without a self-contained justification in the main text, the theoretical backbone of the calibration procedure is opaque.

### Minor
- **The τ-optimization per test point (lines 162–166) is not covered by the theory.** Theorem 4.1 is stated for "any τ ∈ (0,1)" but for a fixed τ. Selecting τ in a data-dependent way per test point to maximize the LPB introduces additional variability not addressed by the current theoretical guarantee. The paper should either prove the guarantee holds uniformly over τ or provide empirical validation that optimization does not degrade coverage.

- **The calibration set discards all censored observations (Algorithm 1, step 3 restricts to e=1), reducing effective sample sizes significantly.** The paper does not report censoring rates or effective calibration sizes per treatment in any experiment, making it difficult to assess when the method is practically applicable. In the real dataset (541 patients, 4 regimens, typical lung cancer censoring ~30–50%), effective calibration sizes could be as low as 20–60 per treatment, and with estimated weights this may produce unreliable quantile estimates.

### Trivial
- None.

## Nice-to-Haves
- Report censoring rates and effective calibration sample sizes per treatment arm in all experiments; characterize how coverage and LPB informativeness degrade as censoring increases.
- Include an empirical study that explicitly addresses whether τ-optimization affects coverage.
- Add a comparison in synthetic experiments to Candès et al. (2023) under Type-I censoring scenarios where that method applies.

## Removed Points
These points were raised in the input review but removed with justification:
- "No comparison to Candès et al. (2023) in experiments" — Candès et al. handles Type-I censoring only (a different setting); the paper's framing is adequate.
- "No standard errors in Table 1" — minor presentation issue, not substantive.
- "Binary treatment assumption vs real data" — the paper explicitly says "for simplicity, we consider binary treatments" (line 48) and the real-data application applies per-treatment models, which is a straightforward extension.
- "Theorem 4.2 is asymptotic" — doubly robust guarantees are standardly asymptotic; this is not a meaningful limitation.
- "PAC vs exact framing clarification" — subsumed under the major weakness about overclaiming.
- Various generic category-sweep concerns without specific anchors in the paper text.

## Novel Insights
None beyond the paper's own contributions.

## Suggestions
1. **Reframe all "exact" claims** to match Theorem 4.1. State the bound as "1 − α minus a weight-estimation error term that vanishes with consistent estimation" rather than "exact." This would strengthen, not weaken, the paper.
2. **Clarify the derivation** in equation (1) by providing a self-contained justification for the inequality direction and the role of each step, or explicitly reference the appendix lemma that fills the gap.
3. **Report effective sample sizes and censoring rates** in all experiments; demonstrate how performance degrades as censoring increases.
4. **Address the τ-optimization issue** by showing coverage is not degraded, or amend the theory.

## Score and Decision

**Score: 5.0**
**Decision: Reject**

### Calibration Anchors
| Path | Avg Score | Round | Itemized | Comparison |
|------|-----------|-------|----------|------------|
| JQtuCumAFD — Conformalized Survival Analysis for General Right-Censored Data | 5.50 | R1 | Yes | Same topic (conformal LPB for right-censored survival). Stronger negatives (incremental at -2.54) but no overclaiming issue. Accepted. My paper has similar theoretical positives but adds the credibility problem of claiming "exact" coverage. |
| AKAz88zYLB — Conformal Prediction for Dose-Response Models | 5.80 | R1 | Yes | Weighted conformal for causal inference. "No theoretical guarantee" (-0.90) comparable to my paper's overclaiming (-0.75). My paper has stronger theory but also the overclaiming issue. |
| pVL4bYKOGM — Conformal Prediction for Causal Effects of Continuous Treatments | 5.50 | R2 | Yes | Similar "exact" overclaiming noted by reviewer (favorability=6.11). Weaker experimental validation. My paper has stronger empirical evaluation. |
| XgYPzNtz0s — Survival Analysis via Density Estimation | 4.60 | R2 | Yes | Different methodology for survival analysis. Simpler contribution, no overclaiming issues. My paper is stronger in theory and evaluation. |
| Nfd7z9d6Bb — Probabilistic Conformal Prediction with Approximate Conditional Validity | 6.00 | R1 | Yes | Clean theoretical results, thorough experiments. Higher quality than my paper. |
| v8RDgaEtE2 — Regression Conformal Prediction under Bias | 2.50 | R1 | Yes | Weak theoretical rigor, elementary results. Significantly weaker than my paper. |

**Placement rationale:** The paper's strongest items (theoretical contributions at favorability ~11, empirical evaluation at ~9.4) match well with the JQtuCumAFD anchor at 5.50. However, my paper has a unique negative (-0.75 for overclaiming "exact" coverage) that the anchor paper does not share, while the anchor paper's negatives are worse (incremental contribution at -2.54, no comparisons at -2.50). On balance, the overclaiming issue is a credibility problem that drags this paper slightly below the 5.50 anchor, placing it at 5.0 — borderline, with the current presentation insufficient for acceptance but the underlying method potentially salvageable with honest reframing and clarification.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>